Vanguard Group Inc Ovid Therapeutics Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,976,308 shares of OVID stock, worth $2.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,976,308

Previous 2,989,777 0.45%

Holding current value

$2.29 Million

Previous $9.63 Million 5.71%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.72 - $4.04 $36,635 - $54,414	-13,469 Reduced 0.45%	2,976,308 $9.08 Million
Q4 2023 Feb 14, 2024	BUY	$2.98 - $3.78 $69,612 - $88,300	23,360 Added 0.79%	2,989,777 $9.63 Million
Q3 2023 Nov 14, 2023	BUY	$3.23 - $3.97 $217,020 - $266,740	67,189 Added 2.32%	2,966,417 $11.4 Million
Q2 2023 Aug 14, 2023	BUY	$2.53 - $3.89 $730,223 - $1.12 Million	288,626 Added 11.06%	2,899,228 $9.51 Million
Q1 2023 May 15, 2023	BUY	$1.88 - $2.85 $54,268 - $82,268	28,866 Added 1.12%	2,610,602 $6.74 Million

Q4 2022 Feb 10, 2023	BUY	$1.43 - $1.86 $1,638 - $2,131	1,146 Added 0.04%	2,581,736 $4.8 Million
Q3 2022 Nov 14, 2022	BUY	$1.85 - $2.26 $84,175 - $102,829	45,500 Added 1.79%	2,580,590 $4.75 Million
Q2 2022 Aug 12, 2022	SELL	$1.69 - $3.31 $1.95 Million - $3.82 Million	-1,152,819 Reduced 31.26%	2,535,090 $5.45 Million
Q1 2022 May 13, 2022	BUY	$2.65 - $3.49 $650,021 - $856,065	245,291 Added 7.13%	3,687,909 $11.6 Million
Q4 2021 Feb 14, 2022	BUY	$3.13 - $3.73 $189,480 - $225,803	60,537 Added 1.79%	3,442,618 $11.1 Million
Q3 2021 Nov 12, 2021	SELL	$3.31 - $4.04 $408,970 - $499,166	-123,556 Reduced 3.52%	3,382,081 $11.4 Million
Q2 2021 Aug 13, 2021	BUY	$3.3 - $4.49 $11.6 Million - $15.7 Million	3,505,637 New	3,505,637 $13.7 Million

Others Institutions Holding OVID

# of Institutions

Shares Held

43.2M

Call Options Held

5.9K

Put Options Held

300

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $54.2M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Ovid Therapeutics Inc. Transaction History